Some say the economy is terrible. I’m not going to disagree though, it is a wonderful time for a bargain hunting company with a wad of cash. Of course, Memory isn’t/wasn’t without skeletons in its closet but scooping up a company with multiple novel development candidates in early and phase 2a clinical trials for $50M (not including cash on hand or liabilities) is a phenomenal deal.
Now, Roche already had a license to the nicotinic alpha-7 agonists anyway (in fact, $17M due at the completion of phase 2a for R3487), but why share in the glory when you can have it all to yourself for less with a few other programs thrown in as a kicker (PDE4, L-type calcium modulator, 5-HT6 antagonists)?
Roche signs definitive agreement to acquire Memory Pharmaceuticals
(Via Roche Media News.)
Theoretically Related Posts
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)